HK1143756A1 - Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain - Google Patents

Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain

Info

Publication number
HK1143756A1
HK1143756A1 HK10110430.5A HK10110430A HK1143756A1 HK 1143756 A1 HK1143756 A1 HK 1143756A1 HK 10110430 A HK10110430 A HK 10110430A HK 1143756 A1 HK1143756 A1 HK 1143756A1
Authority
HK
Hong Kong
Prior art keywords
phenylamides
sulfonyl
pain
substituted
treatment
Prior art date
Application number
HK10110430.5A
Other languages
English (en)
Inventor
Karl Rudolphi
Martin Michaelis
Hans Guehring
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HK1143756A1 publication Critical patent/HK1143756A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
HK10110430.5A 2007-10-05 2010-11-09 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain HK1143756A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07019521 2007-10-05
US1525607P 2007-12-20 2007-12-20
EP08013725 2008-07-31
PCT/EP2008/007953 WO2009043495A1 (en) 2007-10-05 2008-09-20 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain

Publications (1)

Publication Number Publication Date
HK1143756A1 true HK1143756A1 (en) 2011-01-14

Family

ID=40042693

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10110430.5A HK1143756A1 (en) 2007-10-05 2010-11-09 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain

Country Status (17)

Country Link
US (1) US8518998B2 (xx)
EP (1) EP2207541B1 (xx)
JP (1) JP5487107B2 (xx)
KR (1) KR20100063109A (xx)
CN (1) CN101815514B (xx)
AR (1) AR071049A1 (xx)
BR (1) BRPI0817483A2 (xx)
CA (1) CA2706241C (xx)
CL (1) CL2008002942A1 (xx)
ES (1) ES2527948T3 (xx)
HK (1) HK1143756A1 (xx)
IL (1) IL204668A (xx)
MX (1) MX2010003071A (xx)
PA (1) PA8797801A1 (xx)
PE (1) PE20090961A1 (xx)
TW (1) TW200932247A (xx)
WO (1) WO2009043495A1 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2013025425A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
US8906904B2 (en) 2012-09-07 2014-12-09 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
CA2904160C (en) * 2013-03-15 2022-08-23 The California Institute For Biomedical Research Phenyl sulfonamide derivatives and use thereof in the treatment of arthritis
AU2015292833B2 (en) 2014-07-22 2019-11-28 Boehringer Ingelheim International Gmbh Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
EP2990403A1 (en) * 2014-08-29 2016-03-02 Novartis Tiergesundheit AG Anthranilamides, sulfonamides and nitro analogues derived therefrom as anthelmintics
CN104892466B (zh) * 2015-04-30 2018-05-29 中国科学技术大学 一种苯胺磺酰类化合物的合成及其作为hiv病毒抑制剂的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US684287A (en) * 1900-03-15 1901-10-08 Millhiser Mfg Company Bag-stringing machine.
KR100720844B1 (ko) * 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 n-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE19943634A1 (de) * 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10122894A1 (de) * 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DOP2003000556A (es) * 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
US20040192680A1 (en) * 2002-12-20 2004-09-30 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
DE102005031575A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Förderung der Wundheilung

Also Published As

Publication number Publication date
US20110021505A1 (en) 2011-01-27
JP2010540581A (ja) 2010-12-24
CL2008002942A1 (es) 2009-06-05
AR071049A1 (es) 2010-05-26
CA2706241C (en) 2015-12-22
EP2207541B1 (en) 2014-10-29
IL204668A0 (en) 2010-11-30
BRPI0817483A2 (pt) 2016-07-26
WO2009043495A1 (en) 2009-04-09
JP5487107B2 (ja) 2014-05-07
CN101815514A (zh) 2010-08-25
PE20090961A1 (es) 2009-08-10
CN101815514B (zh) 2012-05-09
CA2706241A1 (en) 2009-04-09
TW200932247A (en) 2009-08-01
MX2010003071A (es) 2010-04-01
ES2527948T3 (es) 2015-02-02
US8518998B2 (en) 2013-08-27
PA8797801A1 (es) 2009-06-23
EP2207541A1 (en) 2010-07-21
AU2008306207A1 (en) 2009-04-09
IL204668A (en) 2013-10-31
KR20100063109A (ko) 2010-06-10

Similar Documents

Publication Publication Date Title
GB2439393B (en) Cannabinoids for use in the treatment of neuropathic pain
BRPI1007877A2 (pt) "inibidores de dpp-iv para o tratamento de diabetes em pacientes pediátricos"
ZA200907215B (en) Uses of oligomers of lactic acid in the treatment of gynaecological disorders
SI1978947T1 (sl) Nitrooksiderivati za uporabo pri zdravljenju mišičnih distrofij
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
IL205562A0 (en) Benzodiazepinone compounds useful in the treatment of skin conditions
SI2137141T1 (sl) Arilamidi bifenil-4-il-sulfonske kisline in njihova uporaba kot terapevtska sredstva
HK1203160A1 (en) Tapentadol for the treatment of pain in arthrosis (tapentadol)
HK1209053A1 (zh) 地來西坦在慢性疼痛的治療中的用途
HK1143756A1 (en) Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
HK1160471A1 (en) Aminophosphinic derivatives that can be used in the treatment of pain
PL2323644T3 (pl) N-podstawione benzenopropanoamidowe lub benzenopropanoamidowe pochodne do zastosowania w leczeniu bólu
IL213703A (en) Compounds for the treatment of pain and other diseases
GB0822486D0 (en) Compounds for use in the treatment of pain
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
EP2488507A4 (en) NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
PT2182954T (pt) Utilização de ácidos nor-biliares no tratamento de arteriosclerose
GB0821594D0 (en) Improvements in or relating to the treatment of tissue damage
IL219444A (en) Procine for use in the treatment of blood cell infections
GB0814043D0 (en) The treatment of skin disorders
GB0722338D0 (en) Novel use and treatment
GB0820562D0 (en) Novel use and treatment
GB0712390D0 (en) Use of compounds in the treatment of pain and irritable bowel syndrome

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160920